The company shows strong revenue growth, driven by Tyvaso (+33% YoY), and maintains high margins and low debt burden, with a 39% growth potential. Key growth drivers include Tyvaso's expansion ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10.

MannKind’s stock has fluctuated due to Tyvaso DPI’s Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI’s ...

Leerink analyst Roanna Ruiz lowered the firm’s price target on United Therapeutics (UTHR) to $420 from $430 and keeps an ...

Dosage for transition from Tyvaso Inhalation Solution: see full labeling. Risk of symptomatic hypotension in those with low systemic arterial pressure. Hepatic insufficiency; titrate slowly.

Its key medications—Remodulin, Tyvaso, and Orenitram—are sold to patients, hospitals, and specialty pharmacies. United Therapeutics Corporation (NASDAQ:UTHR) ended 2024 with record revenue and ...

The company reported a 23% year-over-year revenue increase, reaching $748.9 million, largely driven by a 33% rise in Tyvaso sales, which totaled $433.8 million. Products like Orenitram and ...

Earlier this month, the company announced that it had completed the full enrollment in the phase III TETON 1 study, which is evaluating the use of Tyvaso (treprostinil) inhalation solution ...

United Therapeutics’ Q4 earnings brought clarity on the outlook for the base commercial business and Tyvaso’s future growth trajectory, suggesting that gross-to-net impact from recent ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.